Precision medicine

Methuselah Foundation Launches $1 Million Competition to Stimulate Development of Animal-Free Precision Medicine

Retrieved on: 
Tuesday, September 20, 2022
Animal Free Research UK, Regenerative medicine, Precision medicine, Wake Forest School of Medicine, Time, Human, Methuselah, Twitter, Longevity, FDA, Gobel, LinkedIn, Methuselah Foundation, Foundation, Patient, Hebrew Bible, CEO, Instagram, Wake Forest Institute for Regenerative Medicine, Wake Forest, Research, Medicine, Bible, Animal, Pharmaceutical industry, Facebook

DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Methuselah Foundation, the original biomedical charity devoted to extending the human health span, announced a $1 million competition to encourage innovation that will enable medicine to move away from unreliable animal testing.

Key Points: 
  • Though medicine relies heavily on animal testing for the development of new drugs and therapies, it is unreliable, ineffective and costly.
  • Today, development of a new oncology drug can cost up to $5 billion and take up to 15 years.
  • Because it uses bioengineered human tissue, it promises to be a superior alternative to animal testing for research, clinical trials and precision medicine.
  • "I am excited to support this Animal Free Precision Medicine initiative and the incentives it creates to accelerate this new era of medical research."

BioAI Adds New Investors and World-leading Scientific Expertise to Underpin Next Stage of Global Biopharma Partnerships

Retrieved on: 
Tuesday, September 20, 2022
GM, MPH, University, Precision medicine, Laboratory, Molecular biology, Machine learning, Digital health, LLC, Hospital, Organization, Growth, Boston Children's Hospital, Investment, Patient, Cancer, CEO, Genetics, Molecular epidemiology, Public health, CSO, Pathology, Francis A. Wallar, Harvard Medical School, Genomics, Research, Biotechnology, Multimedia, Health, SVP, Bio-Med Science Academy, Medical device, Management, Doctor of Philosophy

GOFFSTOWN, N.H., Sept. 20, 2022 /PRNewswire/ -- Bio-AI Health, an emerging leader in the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, today announced its first external investment, from digital health investors BioMed Investments LLC. The company also announced the appointment of Dr. Tom Chittenden, PhD, DPhil, PStat, a pioneer in the use of machine learning and probabilistic programming to map the causal pathways of disease initiation and progression, as chief scientific officer and president of R&D, as well as the addition of genomics industry leader Dr. Gina Wallar, PhD, MPH to its scientific advisory board and Dick Anagnost and Andy Crews of Bio-Med to its board of directors.

Key Points: 
  • We are thrilled to have Tom leading this effort, and to welcome Gina Wallar, PhD to our stellar advisory board.
  • As successful investors and serial entrepreneurs, Dick Anagnost and Andy Crews bring outstanding and relevant expertise in building organizations and mergers & acquisitions to our board of directors."
  • Dr. Chittenden holds PhDs in both molecular biology and computational statistics and has published numerous pathbreaking scientific papers in causal machine learning.
  • Bio-Med Investments LLC is focused on investing capital in early-stage digital health startup companies like Bio-AI Health.

BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing

Retrieved on: 
Tuesday, September 20, 2022
VP, Precision medicine, Twitter, FDA, Blood, Quality, Cell, Serum, CFR, Fraction, Mesa, Good manufacturing practice, Tissue, Science, AB, Research, Pharmacokinetics, Hepatocyte, Multimedia, Drug discovery, GMP, View, Vaccine

WESTBURY, N.Y., Sept. 20, 2022 /PRNewswire/ -- BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART™ leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.

Key Points: 
  • Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.
  • "This GMP-grade leukopak product introduction underscores BioIVT's commitment to being a high quality, global immune cell provider," said BioIVT CEO Dr. Richard Haigh.
  • With the VivoSTART leukopak launch, our customers can now transition seamlessly from research to manufacturing without compromising product integrity."
  • GMP-compliant VivoSTART leukopaks will serve as the ideal starting material for allogeneic ex vivo cell therapies and other advanced therapeutic applications.

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

Retrieved on: 
Tuesday, September 20, 2022
Securities Exchange Act of 1934, Workflow, Adoption, Precision medicine, Time, Infection, COVID-19, Securities Act of 1933, ID, Curetis, AMR, Private Securities Litigation Reform Act, European Investment Bank, U.S. Securities and Exchange Commission, CEO, Technology, Goal, Solution, Nasdaq, Nadine Opgen-Rhein, NGS, Security (finance), GLOBE, Hospital, A30, R, Medical device, Vaccine, MD, Developing country

The Unyvero A30 RQ platform is a sample to answer instrument running a disposable one-time use cartridge that can test for up to 33 diagnostic targets from a single specimen.

Key Points: 
  • The Unyvero A30 RQ platform is a sample to answer instrument running a disposable one-time use cartridge that can test for up to 33 diagnostic targets from a single specimen.
  • The R&D contract and associated funding will support the required R&D efforts on our side and expedite such development.
  • About OpGen, Inc. OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding the R&D collaboration agreement entered into by OpGens subsidiary Curetis GmbH and FIND, the global foundation for innovative new diagnostics.

DNAnexus Appoints Chief Commercial Officer to Accelerate Global Adoption of Leading Biomedical Data-Driven Technology Platform

Retrieved on: 
Tuesday, September 20, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Biometrics, Technology, Infectious Diseases, Genetics, Health Technology, Security, Science, Health, Software, Precision medicine, Safety, Blackstone, CA Technologies, FDA, Privacy, Health, Industry, Academic health science centre, Radford University, IBM, CEO, ERT, UK Biobank, Science, Genomics, GE Healthcare, Marketing, View, Medical device, DNAnexus, Oracle

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the appointment of Stephen Nuckols as Chief Commercial Officer.

Key Points: 
  • DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the appointment of Stephen Nuckols as Chief Commercial Officer.
  • Steve brings decades of valuable industry experience managing cross-functional teams and scaling commercial operations for leading software companies, said Richard Daly, CEO at DNAnexus.
  • He previously served as ArisGlobals Chief Revenue Officer, where he was responsible for leading all aspects of the commercial organization.
  • Prior to ArisGlobal, he served as Executive Vice President and Chief Commercial Officer at ERT, a leading data and technology company supporting clinical drug development companies.

Alzheon Appoints Glenn Pauly as Head of Commercial

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cerebral edema, Precision medicine, Neurodegeneration, Safety, Neurotoxicity, Plaque, Risk, Brain, MD, AD, Food, Biomarker, APOE4, Alzheimer's disease, Ageing, Population, Health, National Institute on Aging, NDA, Head, Patient, Â, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Johnson & Johnson, Technology, AstraZeneca, Pathology, Commercial, Doctor of Philosophy, Fast Track, Caregiver, Dementia, Biogen, National Institute, Pharmaceutical industry, Medical imaging, Genentech, Alzheon

Alzheon, Inc. , a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimers disease (AD) and other neurodegenerative disorders, today announced the appointment of Glenn E. Pauly as Head of Commercial.

Key Points: 
  • Alzheon, Inc. , a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimers disease (AD) and other neurodegenerative disorders, today announced the appointment of Glenn E. Pauly as Head of Commercial.
  • Mr. Pauly brings to Alzheon more than 20 years of commercial launch experience in the biopharmaceutical industry.
  • He has extensive experience with launching disease-modifying agents in multiple therapeutic areas working across multiple commercial functions including sales, account management and market access.
  • It is an incredibly exciting time to be joining Alzheon, said Mr. Pauly.

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Retrieved on: 
Tuesday, September 20, 2022
Neurology, Biometrics, Biotechnology, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Cerebral edema, Good laboratory practice, Plasma, Neurodegeneration, Precision medicine, Safety, Neurotoxicity, Plaque, Ageing, Risk, Brain, MD, Disease, Biomarker, Food, APOE4, MRI, Population, National Institute on Aging, Genotype, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ADAS, CEO, Technology, University of Gothenburg, Female, Pathology, Culture Collection (University of Gothenburg), Doctor of Philosophy, Fast Track, Dementia, Neuron, University, National Institute, Cerebrospinal fluid, Medical imaging, Pharmaceutical industry, Alzheimer's disease, Alzheon

In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.

Key Points: 
  • In mechanism of action studies, ALZ-801 fully inhibited the formation of amyloid oligomers at the Phase 3 clinical dose.
  • APOE4 genotype, the leading risk factor for AD after aging, is associated with a several-fold higher brain burden of neurotoxic amyloid oligomers.
  • P-tau181 levels rise with AD progression and clinical deterioration of patients, and have been shown to fall in response to clinically effective disease modifying treatments in Alzheimers.
  • Our lead Alzheimers clinical candidate, ALZ-801 (valiltramiprosate) , is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD.

Zynx Health Introduces Complimentary Monkeypox Order Set and Care Plan Bundle

Retrieved on: 
Tuesday, September 20, 2022
General Health, Data Management, Technology, Infectious Diseases, Hospitals, Other Communications, Health Technology, Public Relations, Investor Relations, Marketing, Communications, Practice Management, Health, Precision medicine, Center, Zynx Health, COVID-19, Twitter, MD, World, World Health Organization, Prescription, LinkedIn, First Databank, Industry, Patient, Hearst, Technology, Korea Disease Control and Prevention Agency, PDF, Monkeypox, Hospital, MCG, FDB, MHK, Pharmaceutical industry

Zynx Health today announced that it has published new order set and care plan guidelines to aid clinicians in the treatment of patients diagnosed with monkeypox.

Key Points: 
  • Zynx Health today announced that it has published new order set and care plan guidelines to aid clinicians in the treatment of patients diagnosed with monkeypox.
  • As monkeypox cases continue to rise, and with hospitals still facing shortfalls in the wake of the COVID-19 pandemic, our Zynx clinicians have developed and deployed this comprehensive order set and care plan bundle to alleviate the burden of researching the underlying evidence and then building the associated clinical decision support from scratch, said Chuck Tuchinda, MD, president of Zynx Health.
  • The Zynx Clinical Team will continue to update its monkeypox care guidance as new evidence emerges and best-practice recommendations evolve.
  • With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models.

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

Retrieved on: 
Monday, September 19, 2022
Precision medicine, Laboratory, RNA transfection, Gene, Private Securities Litigation Reform Act, Synthetic biology, Invention, U.S. Securities and Exchange Commission, Forward-looking statement, CEO, Technology, Doctor of Philosophy, NASDAQ, SAN, RNA, Research, DNA, Security (finance), GLOBE, SEC, Gibson assembly, Pharmaceutical industry, Vaccine, Book, Codex

SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows.

Key Points: 
  • SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows.
  • Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges.
  • As inventors of the industry-standard Gibson Assembly method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets.
  • Codex DNA, the Codex DNA logo, Gibson Assembly, BioXp,and RapidAMP are trademarks of Codex DNA Inc.

CareDx Showcases Transplant Digital Leadership in Patient Care at 2022 MEET Conference

Retrieved on: 
Monday, September 19, 2022
General Health, Other Health, Health, Genetics, Health Technology, Precision medicine, Time, Transplant, MD, UNOS, Health, Hotel manager, NASEM, Health equity, Patient, Length of stay, National Academy of Medicine, CEO, Solution, Annual report, Nasdaq, EMR, National academy, Caregiver, Conference, SEC, Education, Dentistry, Medical device, Engineering, Medicine

The CareDx user conference brings together transplant administrators, quality managers, transplant clinicians, and organ procurement organization professionals to showcase digital health innovations, share best practices, and discuss emerging trends surrounding transplant operations, quality improvement, patient management, and health equity.

Key Points: 
  • The CareDx user conference brings together transplant administrators, quality managers, transplant clinicians, and organ procurement organization professionals to showcase digital health innovations, share best practices, and discuss emerging trends surrounding transplant operations, quality improvement, patient management, and health equity.
  • Over the past few years, we have invested in patient-centered digital health solutions aimed at improving outcomes and the complex transplant journey, said Reg Seeto, CEO and President of CareDx.
  • CareDx is a leading provider of digital health solutions that powerfully link participating transplant centers, healthcare providers, and patients in better navigating the complex transplant journey to improve patient care.
  • CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.